BEXSERO

BEXSERO multicomponent meningococcal B vaccine (recombinant, adsorbed) is a vaccine for the prevention of meningococcal disease caused by Neisseria meningitidis group B bacteria in individuals from 2 months through 25 years of age. BEXSERO is not expected to protect against all circulating meningococcal serogroup B strains and does not offer protection against strains A, C, Y, and W-135. As with any vaccine, BEXSERO may not fully protect all of those who are vaccinated. BEXSERO does not treat or reduce the consequences of meningococcal disease, including meningitis, sepsis, and death. The very common side effects (may affect more than 1 in 10 people) after vaccination with BEXSERO (reported in all age groups) were pain/tenderness at the injection site, redness at the injection site, swelling of the skin at the injection site, and hardness of the skin at the injection site. In infants and children (up to 10 years of age), fever can occur more frequently when BEXSERO is given at the same..

Primary location: Mississauga Canada